PMID- 22393992
OWN - NLM
STAT- MEDLINE
DCOM- 20120713
LR  - 20220318
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 12
IP  - 11
DP  - 2011
TI  - HLA class II variants in Chinese breast cancer patients.
PG  - 3075-9
AB  - Alterations of human leukocyte antigen (HLA) class II molecules are relevant to 
      the development of breast cancer and metastatic progression. However, the role of 
      HLA class II polymorphisms in the pathogenesis and progression of breast cancer 
      is unclear. This study aimed to investigate the association between HLA class II 
      variants and breast cancer susceptibility and prognosis in a Chinese population. 
      Sixteen variants in HLA class II were detected with the Sequenom MassArray(R) iPLEX 
      System in 216 breast cancer patients and 216 healthy controls. An association 
      analysis based on unconditional logistic regression was carried out to determine 
      the odds ratio (OR) and 95% confidence interval (95% CI) for each SNP. Stratified 
      analysis by oestrogen receptor (ER) and progesterone receptor (PR) status was 
      also performed. Among 16 variants, only seven conformed to Hardy-Weinberg 
      proportions in the controls. None of these seven variants showed statistically 
      significant differences between the case and control groups in this Han Chinese 
      population. However, chr6_32737733, a variant in HLA-DQB1, showed significant 
      associations with both ER-negative and PR-negative breast cancer in the best fit 
      to the dominant model. Furthermore, another significant correlation was seen 
      between chr6_32606112, a variant in HLA-DRB5, and PR positivity. These results 
      indicate that although no breast cancer risk variants in HLA class II were found 
      in this Chinese population, HLA-DQB1 chr6_32737733 may be involved in determining 
      a poor prognosis, whereas HLA-DRB5 chr6_32606112 may relate to a good prognosis.
FAU - Yang, Xue-Xi
AU  - Yang XX
AD  - School of Biotechnology, Southern Medical University, Guangzhou, China.
FAU - Pan, Hua-Zheng
AU  - Pan HZ
FAU - Li, Pei-Yi
AU  - Li PY
FAU - Li, Fen-Xia
AU  - Li FX
FAU - Xu, Wei-Wen
AU  - Xu WW
FAU - Wu, Ying-Shong
AU  - Wu YS
FAU - Yao, Guang-Yu
AU  - Yao GY
FAU - Li, Ming
AU  - Li M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQB1 antigen)
RN  - 0 (HLA-DRB5 Chains)
SB  - IM
MH  - Breast Neoplasms/*genetics/*immunology/mortality
MH  - Case-Control Studies
MH  - China
MH  - Disease Progression
MH  - Female
MH  - *Genes, MHC Class II
MH  - Genetic Variation
MH  - HLA-DQ beta-Chains/genetics/immunology
MH  - HLA-DRB5 Chains/genetics/immunology
MH  - Humans
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide
MH  - Prognosis
EDAT- 2011/01/01 00:00
MHDA- 2012/07/14 06:00
CRDT- 2012/03/08 06:00
PHST- 2012/03/08 06:00 [entrez]
PHST- 2011/01/01 00:00 [pubmed]
PHST- 2012/07/14 06:00 [medline]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2011;12(11):3075-9.